Investment Information

With transparent disclosure of information and communication with markets,
we will grow along with shareholders.

HanAll's Partner HBM Announces IND Approval for Phase 2 of Batoclimab in CIDP in China


Related Data

HanAll Biopharma (KRX: 009420.KS) today announced that its partner for HL161 (batoclimab) & HL036 (tanfanercept)​ for the Chinese market, Harbour BioMed, has received IND approval for Phase 2 of batoclimab in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) in China. The company is now pursuing 5 autoimmune diseases including myasthenia gravis (MG), grave’s ophthalmopathy (GO), adult immune thrombocytopenia (ITP), neuromyelitis optica spectrum disorder (NMOSD), and​ chronic inflammatory demyelinating polyneuropathy (CIDP)​ in the region.


For more information, please refer to the link below. 

- HBM press release link: